Interleukin 11 ( DrugBank: Interleukin 11 )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
288自己免疫性後天性凝固因子欠乏症3

288. 自己免疫性後天性凝固因子欠乏症


臨床試験数 : 205 薬物数 : 238 - (DrugBank : 31) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 26
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00994929
(ClinicalTrials.gov)
January 201012/10/2009Efficacy and Safety of IL-11 in DDAVP UnresponsivePhase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVPHemophilia A;Von Willebrand DiseaseBiological: Neumega (Oprelvekin, Interleukin 11, IL-11)University of PittsburghNULLCompleted18 YearsN/AAll9Phase 2United States
2NCT00524225
(ClinicalTrials.gov)
February 200831/8/2007IL-11 in Adults With Von Willebrand Disease Undergoing SurgeryPhase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease Undergoing SurgeryVon Willebrand DiseaseDrug: Neumega (Oprelvekin, Interleukin 11, IL-11)Margaret RagniUniversity of North Carolina;Wyeth is now a wholly owned subsidiary of PfizerTerminated18 YearsN/AAll3Phase 2United States
3NCT00524342
(ClinicalTrials.gov)
January 200831/8/2007IL-11 in Women With Von Willebrand Disease and Refractory MenorrhagiaPhase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Women With Type 1 Von Willebrand Disease and Refractory MenorrhagiaVon Willebrand DiseaseDrug: Oprelvekin, Interleukin 11, IL-11Margaret RagniUniversity of North Carolina;Wyeth is now a wholly owned subsidiary of PfizerCompleted18 Years45 YearsFemale7Phase 2United States